Gilissen Julie, Jouret François, Pirotte Bernard, Hanson Julien
Laboratory of Molecular Pharmacology, GIGA-Molecular Biology of Diseases, University of Liège, Liège, Belgium; Laboratory of Medicinal Chemistry, Centre for Interdisciplinary Research on Medicines (CIRM), University of Liège, Belgium.
Laboratory of Experimental Surgery, GIGA-Cardiovascular Sciences, University of Liège, Liège, Belgium; Division of Nephrology, University of Liège Hospital (ULg CHU), Liège, Belgium.
Pharmacol Ther. 2016 Mar;159:56-65. doi: 10.1016/j.pharmthera.2016.01.008. Epub 2016 Jan 22.
SUCNR1 (or GPR91) belongs to the family of G protein-coupled receptors (GPCR), which represents the largest group of membrane proteins in human genome. The majority of marketed drugs targets GPCRs, directly or indirectly. SUCNR1 has been classified as an orphan receptor until a landmark study paired it with succinate, a citric acid cycle intermediate. According to the current paradigm, succinate triggers SUCNR1 signaling pathways to indicate local stress that may affect cellular metabolism. SUCNR1 implication has been well documented in renin-induced hypertension, ischemia/reperfusion injury, inflammation and immune response, platelet aggregation and retinal angiogenesis. In addition, the SUCNR1-induced increase of blood pressure may contribute to diabetic nephropathy or cardiac hypertrophy. The understanding of SUCNR1 activation, signaling pathways and functions remains largely elusive, which calls for deeper investigations. SUCNR1 shows a high potential as an innovative drug target and is probably an important regulator of basic physiology. In order to achieve the full characterization of this receptor, more specific pharmacological tools such as small-molecules modulators will represent an important asset. In this review, we describe the structural features of SUCNR1, its current ligands and putative binding pocket. We give an exhaustive overview of the known and hypothetical signaling partners of the receptor in different in vitro and in vivo systems. The link between SUCNR1 intracellular pathways and its pathophysiological roles are also extensively discussed.
琥珀酸受体1(或GPR91)属于G蛋白偶联受体(GPCR)家族,该家族是人类基因组中最大的膜蛋白组。大多数已上市药物直接或间接靶向GPCR。在一项具有里程碑意义的研究将琥珀酸受体1与柠檬酸循环中间体琥珀酸配对之前,它一直被归类为孤儿受体。根据目前的范式,琥珀酸触发琥珀酸受体1信号通路以指示可能影响细胞代谢的局部应激。琥珀酸受体1在肾素诱导的高血压、缺血/再灌注损伤、炎症和免疫反应、血小板聚集以及视网膜血管生成中的作用已有充分记载。此外,琥珀酸受体1诱导的血压升高可能导致糖尿病肾病或心脏肥大。对琥珀酸受体1的激活、信号通路和功能的了解在很大程度上仍然不清楚,这需要更深入的研究。琥珀酸受体1作为一种创新药物靶点具有很高的潜力,可能是基础生理学的重要调节因子。为了全面表征该受体,更具特异性的药理学工具,如小分子调节剂,将是一项重要资产。在这篇综述中,我们描述了琥珀酸受体1的结构特征、其目前的配体和假定的结合口袋。我们详尽概述了该受体在不同体外和体内系统中已知的和假设的信号伙伴。琥珀酸受体1细胞内信号通路与其病理生理作用之间的联系也进行了广泛讨论。